Comparative Pharmacology
Head-to-head clinical analysis: ALYQ versus TRYNGOLZA AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYQ versus TRYNGOLZA AUTOINJECTOR.
ALYQ vs TRYNGOLZA (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
Selective inhibitor of protein kinase C theta (PKCθ), reducing T cell activation and cytokine production.
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
0.5 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 21 days (range 14–28 days), consistent with slow clearance from plasma due to target-mediated drug disposition.
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Category C
Category C
Unknown
Unknown